Page 98 - Number One

by by 7% compared to the the first half of 2018 Sales growth was achieved on the the the the hospital hospital products segment by by increasing the the the quantities used in in in in in the the the hospitals in in in in in Vietnam especially anti‐infectious products Starting with 2019 we have obtained marketing authorizations for four other products” the the report states On the the US market exports of of injectable finished products increased by 44% in in in in the the the first half of of of 2019 through the the the award of of of new auctions Sales growth was also influenced by the the the signing of of a a a a a a a a a a partnership with a a a a a a a a a a a a new new local distributor the the the first first delivery being already made in in in in the the the first first quarter of 2019 and a a a a a a a a a a new new delivery being discussed which will materialize in in in the the the fourth quarter of of of this year In the the the first half of of of 2019 the the the company started registering a a a a a a a a a a a package of of of of approximately 35 products the the the the aim of of Antibiotice SA being to to to to export to to to to Ukraine but also to to to to the the the the other territories the the the company’s development concepts “The expansion program to Africa and and the the Middle East continued with with the the the markets of of Iraq Saudi Arabia and and Africa with with the the the registration registration of of of new products Thus in in in the the the first semester of of of 2019 2019 we we obtained registrations for six products products and by the the the the end of of 2019 2019 we we will obtain obtain marketing authorizations for other products products in in in in the the the the anti‐infectious and cardiovascular classes” say the the the the the the authors of of the the the the report In the the the the first half of of 2019 the the the the company consolidated its sales for micronized Nystatin in in in the the United States which remains the the main main market for this this product New collaborative projects have been initiated in in this this area as well which will be be the the source of of growth of traded volumes for the the period 2020–2025 96 Number One
Photo Pixabay
“In Europe the the the the traditional retail markets Germany and and and the the the the Netherlands have increased their quantity demand by about 30% There are also new new markets such as as the UK and and and and Poland where new new projects with local producers of oral suspensions and and and ova based on on on micronized Nystatin have been started” the the the the report shows In the the the the the the first half of of of 2019 the the the the the the value of of of the the the the the the relevant market market (the market market of of of of the the the the the the the products in in in the the the the the the the portfolio of of Antibiotice SA taken into account in in in the the the the company’s strategy) was RON 1 05 billion 8 5% more than in the same period last year The consumption on on on this market was 69 9 9 million boxes of of which Antibiotice SA has a a a a a share of of 22 2% with the 15 5 5 5 million boxes sold Prescription products (RX) accounted for 58 7% of the the total value sales on on on on the the relevant market (RON 615 8 8 million) 2 6% more than last year During the the same period non‐prescription products (OTC) accounted for 41 3% of the the total (RON 432 9 million) In the the first semester of this year the the production achieved was 320 million pharmaceutical units comparable to to the the the same period of of of last year The total value of of of the the the the production in in the the the the first semester of of of 2019 was RON 228 4 million Since 1997 the the the the securities issued by Antibiotice SA have been listed in in the the the PREMIUM category of the the the Bucharest Stock Exchange under
the the symbol ATB The company has a a a a a a a a a a a a capitalization of RON 349 09 million and approximately 1 400 employees